Oncology Data Advisor - Data Hub: Genitourinary Cancers

Prostate Cancer Awareness Month With Ulka Vaishampayan, MD

In honor of Prostate Cancer Awareness Month, Oncology Data Advisor Editorial Board Member Ulka Vaishampayan, Professor of Internal Medicine at the University of Michigan Rogel Cancer Center, sat down to discuss the importance of bringing awareness to prostate cancer, up-to-date diagnostic techniques, and updates in therapeutic selection and treatment.

Prostate Cancer Awareness Month With Ulka Vaishampayan, MD

Raising Awareness of Prostate Cancer in Transgender Women With Farnoosh Nik-Ahd, MD, and Stephen Freedland, MD

This interview in honor of Prostate Cancer Awareness Month features Dr. Stephen Freedland, Urologist at Cedars-Sinai Medical Center and Oncology Data Advisor Editorial Board Member, and Dr. Farnoosh Nik-Ahd, Urology Resident at the University of Cali...

Metastatic Castration-Sensitive Prostate Cancer: Real-World Characteristics and Treatment by Disease Volume With Stephen Freedland, MD

At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Stephen Freedland, Professor of Urology at Cedars-Sinai Medical Center, sat down with Oncology Data Advisor to discuss his abstract regarding real-world characteristics an...

Prostate Cancer Awareness Month With Ulka Vaishampayan, MD

Oncology Data Advisor® · Prostate Cancer Awareness Month With Ulka Vaishampayan, MD In honor of Prostate Cancer Awareness Month, Oncology Data Advisor Editorial Board Member Ulka Vaishampayan, Professor of Internal Medicine at the Universi...

Raising Awareness of Prostate Cancer in Transgender Women With Farnoosh Nik-Ahd, MD, and Stephen Freedland, MD

Oncology Data Advisor® · Raising Awareness of Prostate Cancer in Transgender Women: Farnoosh Nik-Ahd and Stephen Freedland This interview in honor of Prostate Cancer Awareness Month features Dr. Stephen Freedland, Urologist at Cedars-Sinai...

Metastatic Castration-Sensitive Prostate Cancer: Real-World Characteristics and Treatment by Disease Volume With Stephen Freedland, MD

Oncology Data Advisor® · mCSPC: Real World Characteristics and Treatment by Disease Volume With Stephen Freedland, MD At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Stephen Freedland, Professor of Urology at...

Niraparib and Abiraterone Acetate Plus Prednisone Approved for BRCA-Mutated Metastatic CRPC

The FDA has approved the fixed dose combination of niraparib and abiraterone acetate (Akeega™, Janssen Biotech), plus prednisone, for adult patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cance...

Trifluridine and Tipiracil Plus Bevacizumab Approved for Previously Treated Metastatic Colorectal Cancer

The FDA has approved trifluridine and tipiracil (Lonsurf®, Taiho Oncology, Inc.) in combination with bevacizumab (Avastin®, Genentech, Inc.) for treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated wit...

Talazoparib Plus Enzalutamide Approved for HRR Gene–Mutated Metastatic Castration-Resistant Prostate Cancer

The FDA has approved talazoparib (Talzenna®, Pfizer, Inc.) in addition to enzalutamide for homologous recombination repair (HRR) gene–mutated metastatic castration-resistant prostate cancer (mCRPC). Why it matters: "Despite significant advance...